AKT1 and breast carcinoma: Additionally, co-administration of lapatinib and ITCs greatly inhibited survival and migration of drug-sensitive and drug-resistant cell populations through decreased phosphorylation of Akt and VEGF in HER2-positive breast cancer cells [166].